AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
carboprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 502 | 35700-23-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.47 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| S (Water solubility) | 75 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K21,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 36 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 9, 1979 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vomiting | 206.76 | 87.98 | 141 | 1434 | 788152 | 89838720 |
| Nausea | 127.66 | 87.98 | 123 | 1452 | 1110193 | 89516679 |
| Chest discomfort | 126.81 | 87.98 | 57 | 1518 | 138308 | 90488564 |
| Diarrhoea | 98.01 | 87.98 | 99 | 1476 | 939091 | 89687781 |
| Abdominal pain upper | 89.49 | 87.98 | 61 | 1514 | 332613 | 90294259 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vomiting | 221.23 | 89.98 | 141 | 1350 | 910534 | 109677274 |
| Nausea | 143.49 | 89.98 | 123 | 1368 | 1235567 | 109352241 |
| Chest discomfort | 125.04 | 89.98 | 56 | 1435 | 173792 | 110414016 |
| Diarrhoea | 101.32 | 89.98 | 98 | 1393 | 1139407 | 109448401 |
| Abdominal pain upper | 98.47 | 89.98 | 60 | 1431 | 349051 | 110238757 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AD04 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
| FDA CS | M0017805 | Prostaglandins |
| FDA EPC | N0000175454 | Prostaglandin Analog |
| CHEBI has role | CHEBI:36063 | oxytocic |
| CHEBI has role | CHEBI:50691 | abortifacient |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D000020 | Abortifacient Agents, Nonsteroidal |
Related Drugs by ATC class:
G02AD Prostaglandins 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Incomplete miscarriage | off-label use | 156072005 | |
| Induction of labor | off-label use | 236958009 | |
| Cervical ripening procedure | off-label use | 236959001 | |
| Hydatidiform mole, benign | off-label use | 417044008 | |
| Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Third trimester pregnancy | contraindication | 41587001 | |
| Low blood pressure | contraindication | 45007003 | |
| Severe pre-eclampsia | contraindication | 46764007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Acute nephropathy | contraindication | 58574008 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Stenosis of cervix | contraindication | 83536006 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Gynecological Surgery | contraindication | ||
| Inflammatory Disease of Female Pelvic Organs | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.79 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018095 | VUID |
| N0000146433 | NUI |
| D00682 | KEGG_DRUG |
| 58551-69-2 | SECONDARY_CAS_RN |
| 20259 | RXNORM |
| C0007047 | UMLSCUI |
| CHEBI:3403 | CHEBI |
| 87Q | PDB_CHEM_ID |
| CHEMBL1237122 | ChEMBL_ID |
| CHEMBL1237105 | ChEMBL_ID |
| D002260 | MESH_DESCRIPTOR_UI |
| 5281075 | PUBCHEM_CID |
| C062843 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4044 | INN_ID |
| 7B5032XT6O | UNII |
| DB00429 | DRUGBANK_ID |
| 319432 | MMSL |
| 4358 | MMSL |
| d00588 | MMSL |
| 109057004 | SNOMEDCT_US |
| 109058009 | SNOMEDCT_US |
| 373455002 | SNOMEDCT_US |
| 4018095 | VANDF |
| 4022193 | VANDF |
| 001310 | NDDF |
| 004942 | NDDF |
| 7B5032XT6O | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Hemabate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0856 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | NDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9442 | SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| carboprost tromethamine | Human Prescription Drug Label | 1 | 0409-0064 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 16 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-477 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-435 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-179 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-698 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-917 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-919 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 46708-777 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 55150-459 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 55150-459 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 62332-777 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-900 | INJECTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 65145-132 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-579 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| carboprost tromethamine | Human Prescription Drug Label | 1 | 68083-584 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 16 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-825 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 12 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1680 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70512-859 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-112 | SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 71839-137 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 9 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81298-5010 | INJECTION | 250 ug | INTRAMUSCULAR | ANDA | 18 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81665-202 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83270-002 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 11 sections |